Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Fox Chase Cancer Center
Ohio State University Comprehensive Cancer Center
Columbia University
Washington University School of Medicine
University of California, San Francisco
Celgene
National Institutes of Health Clinical Center (CC)
Northwestern University
National Cancer Institute (NCI)